Anne Besancon
Le Mans, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine.
Journal: Cancer medicine
Published: October 20, 2018
Shwachman-Diamond syndrome: a case report
Journal: Annales de biologie clinique
Published: August 07, 2018
Chronic lymphocytic leukemia with t(14 ;18) and trisomy 12: a case report
Journal: Annales de biologie clinique
Published: June 16, 2018
Significant impact of immunosuppression on the incidence of secondary malignancies following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with indolent B-cell neoplasms.
Journal: Leukemia & lymphoma
Published: March 22, 2018
Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine.
Journal: Experimental hematology
Published: March 08, 2018
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Journal: Hematological oncology
Published: April 07, 2016
R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Journal: Annals of hematology
Published: March 24, 2016
Blastic Plasmacytoid Dendritic Cell Neoplasm: From Origin of the Cell to Targeted Therapies.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: March 10, 2016
Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Journal: Annals of hematology
Published: June 02, 2015
Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine.
Journal: European journal of haematology
Published: February 11, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026